Paid Clinical Trials in Des Moines, IA
As of July 2026, 153 paid clinical trials are recruiting in Des Moines, Iowa. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Des Moines offers studies at sites including Iowa Methodist Medical Center for conditions such as Breast Cancer, Malignant Solid Neoplasm, Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Des Moines
Trials by drug in Des Moines
Filter results
149 clinical trials
↓ Download CSVStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Mobile Health for Adherence in Breast Cancer Patients
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
About research studies in Des Moines
Des Moines has approximately 153 recruiting research studies across a wide range of therapeutic areas. Iowa hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Top Research Study Locations in Des Moines
Researchers run research studies in Des Moines, IA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Iowa Methodist Medical Center | Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer, Chronic Lymphocytic Leukemia | 86 |
| UI Health Care Mission Cancer and Blood - Laurel Clinic | Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm, Stage III Laryngeal Cancer AJCC v8 | 82 |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic | Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm, Stage III Laryngeal Cancer AJCC v8 | 80 |
| Mercy Medical Center - Des Moines | Breast Cancer, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8 | 76 |
| Broadlawns Medical Center | Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | 48 |
| Blank Children's Hospital | B Acute Lymphoblastic Leukemia, Malignant Solid Neoplasm, Acute Myeloid Leukemia | 26 |
| Iowa Lutheran Hospital | Metastatic Malignant Neoplasm in the Brain, Stage IIIB Lung Cancer AJCC v8, Acral Lentiginous Melanoma | 21 |
| Medical Oncology and Hematology Associates-Des Moines | Metastatic Malignant Neoplasm in the Brain, Acral Lentiginous Melanoma, Cancer | 5 |
| Mission Cancer and Blood - Laurel | Anatomic Stage IV Breast Cancer AJCC v8, Bone Cancer, NOS, Breast Cancer, NOS | 5 |
| Mission Cancer and Blood - Des Moines | Bone Cancer, NOS, Breast Cancer, NOS, CNS Primary Tumor, NOS | 3 |
| MercyOne Des Moines Medical Center | Lumbar Spinal Stenosis, Mitral Valve Regurgitation | 2 |
| Mission Cancer + Blood - IMMC | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer, KRAS G12C Lung Cancer, Non-Small Cell Lung Cancer | 2 |
| Mission Cancer + Blood - Mission Cancer Foundation | B-Cell Non-Hodgkin Lymphoma, Non-small Cell Lung Cancer, Refractory B-Cell Non-Hodgkin Lymphoma | 2 |
| University of Iowa Health Care | Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia | 2 |
| ACCOMPLISH-2 Research Site | Chronic Weight Management, Obesity, Overweight | 1 |
| Central Iowa Hospital Corp - UnityPoint Health | COPD | 1 |
| Department of Health and Human Services | Mental Health Disorder | 1 |
| Des Moines Oncology Research Association | Chronic Lymphocytic Leukemia (CLL) | 1 |
| Exinia Research | Acute Gout Flare, Acute Gouty Arthritis, Gout Flare | 1 |
| Harbor View Medical | Orthopedic Disorder | 1 |
| Home-based telemedicine | Chronic Granulomatous Disease (CGD) | 1 |
| John Stoddard Cancer Center | Ovarian Cancer | 1 |
| MercyOne Iowa Heart Center | Aortic Stenosis | 1 |
| Mission Cancer & Blood - John Stoddard Cancer Center | Triple Negative Breast Cancer | 1 |
| Mission Cancer + Blood | MF, Myelofibrosis, Post-ET Myelofibrosis | 1 |
Active & Upcoming Studies in Des Moines (2026)
Recruiting trials in Des Moines grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (116 active studies)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations · Phase 3 · SWOG Cancer Research Network
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL · Phase 3 · Alliance for Clinical Trials in Oncology
Mental health & behavior (2 active studies)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Diabetes & metabolic (1 active study)
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) · Phase 3 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Common conditions studied in Des Moines
- Breast Cancer (6 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Malignant Solid Neoplasm (6 active studies). Recruiting Malignant Solid Neoplasm studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Myeloid Leukemia (4 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- B Acute Lymphoblastic Leukemia (4 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Chronic Lymphocytic Leukemia (4 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
Leading research sponsors in Des Moines
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- Children's Oncology Group
- NRG Oncology
Local regulations and guidelines
Clinical trials in Iowa are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Iowa research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Des Moines. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Des Moines
Hipa.ai aggregates every recruiting study in Des Moines from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Des Moines?
There are approximately 153 recruiting clinical trials in Des Moines, Iowa listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Des Moines pay participants?
Most recruiting trials in Des Moines compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Des Moines?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Des Moines?
The most common conditions under active study in Des Moines include Breast Cancer (6), Malignant Solid Neoplasm (6), Acute Myeloid Leukemia (4), Anatomic Stage II Breast Cancer AJCC v8 (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Des Moines?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Des Moines on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Des Moines?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Des Moines?
Recruiting research sites in Des Moines include Iowa Methodist Medical Center, UI Health Care Mission Cancer and Blood - Laurel Clinic, UI Health Care Mission Cancer and Blood - Des Moines Clinic, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Des Moines right now?
The largest active categories in Des Moines are Cancer & tumors (116), Mental health & behavior (2), Diabetes & metabolic (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.